Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood Test
12 déc. 2024 08h00 HE
|
Precede Biosciences, Inc.
Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field todayThere are approximately...
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
15 nov. 2024 21h15 HE
|
Precede Biosciences, Inc.
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic response to Lutetium-PSMABeyond Lutetium-PSMA, these results are...
Circulating Tumor Cells Patent Landscape and Forecast 2024-2032 - The U.S. Leads with Over 4,000 Patent Filings, Driven by Robust R&D Infrastructure and Substantial Investments in Cancer Diagnostics
12 nov. 2024 08h11 HE
|
Research and Markets
Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Circulating Tumor Cells Patent Landscape Report and Forecast 2024-2032" has been added to ResearchAndMarkets.com's offering.The circulating tumor...
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
19 sept. 2024 10h50 HE
|
Precede Biosciences, Inc.
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
15 sept. 2024 06h05 HE
|
Precede Biosciences, Inc.
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET...
Liquid Biopsy Market to Surpass USD 24.14 Billion by 2031, Witnessing 11.21% CAGR Growth | SkyQuest Technology
05 juil. 2024 08h30 HE
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, July 05, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the liquid biopsy market will attain a value of USD 24.14 billion by 2031, with a CAGR of 11.21% during the forecast period...
Global Experts to Convene for the Emerging Technologies for Diagnostics & Liquid Biopsies Conference 2024 in New Orleans (September 26-27th 2024)
26 juin 2024 04h01 HE
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Emerging Technologies for Diagnostics & Liquid Biopsies - New Orleans 2024" conference has been added to ResearchAndMarkets.com's offering. The...
Circulating Biomarkers and Extracellular Vesicles Europe 2024 - Two Day On Site Conference Takes Place in Rotterdam, Netherlands on June 24-25th 2024
06 juin 2024 07h42 HE
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Circulating Biomarkers and Extracellular Vesicles Europe 2024" conference has been added to ResearchAndMarkets.com's offering.The Circulating...
China Biopsy Market Report 2024-2032: Chinese Government Releases 8 Year Plan for Cancer Prevention and Treatment, to Achieve 46.6% Five Year Survival Rate among Cancer Patients by 2030
04 juin 2024 09h18 HE
|
Research and Markets
Dublin, June 04, 2024 (GLOBE NEWSWIRE) -- The "China Biopsy Market Report by Products, Imaging Technology, End-User, and Company Analysis 2024-2032" report has been added to ...
Global Liquid Biopsy Market Report 2024: A Rapidly Growing Sector with Numerous Companies Focusing on Scientific Advancement, Market Set to Reach US$ 13.72 Billion by 2031
04 juin 2024 05h39 HE
|
Research and Markets
Dublin, June 04, 2024 (GLOBE NEWSWIRE) -- The "Global Liquid Biopsy Market, Initiatives, Funding, Major Deals, Company Profiles and Recent Developments - Forecast to 2031" report has been added to ...